Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Orexo AB ( (SE:ORX) ) has shared an update.
Orexo’s annual general meeting re-elected its five-member board, confirmed Friedrich von Bohlen und Halbach as chairman, and retained Ernst & Young as auditor, while approving board and committee fees, including an additional share-based fee to independent directors to strengthen ownership alignment. Shareholders also endorsed guidelines for executive pay, approved the 2025 accounts with no dividend and retained earnings, and discharged the board and CEO from liability.
The meeting granted the board broad mandates to issue new shares of up to 20 percent of share capital and to repurchase and transfer up to 10 percent of the company’s own shares, supporting potential acquisitions, collaborations, capital raising, and incentive plans. In addition, a new long-term incentive program, LTIP 2026, was adopted for up to 70 employees, mirroring the previous year’s plan and underscoring Orexo’s focus on performance-based compensation and capital structure flexibility.
More about Orexo AB
Orexo AB is a Sweden-based specialty pharmaceutical company listed on Nasdaq Stockholm and OTCQX in the U.S. The company focuses on developing and commercializing therapies, particularly within areas such as addiction and other specialty treatments, targeting both domestic and international markets.
Average Trading Volume: 46,753
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK628.6M
Learn more about ORX stock on TipRanks’ Stock Analysis page.